```html

Zollinger’s Ulcers (Zollinger‑Ellison Syndrome)

Overview

Zollinger’s ulcers are a rare type of peptic ulcer that develop as a result of excessive gastric acid secretion caused by a gastrin‑producing tumor known as a gastrinoma. When these tumors occur in the pancreas or duodenum they give rise to Zollinger‑Ellison syndrome (ZES). The condition is named after the physicians who first described it in the 1950s, Drs. Robert Zollinger and Edwin Ellison.

Who it affects: ZES can develop at any age but most patients are diagnosed between 30 and 60 years old. Both men and women are affected, with a slight male predominance (≈55 % male). About 25 % of cases are associated with an inherited condition called multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: Gastrinomas are uncommon, with an estimated incidence of 1–3 cases per million people per year worldwide. Among all peptic ulcer disease (PUD) patients, only 0.5–2 % have ZES.<sup>[1]</sup>

Symptoms

Excess gastric acid leads to ulcers that can occur in the duodenum, jejunum, stomach, or even the esophagus. Symptoms often differ from typical peptic ulcers because they are more severe and refractory to standard therapy.

• Abdominal pain – burning or gnawing pain, usually in the upper abdomen; may be relieved temporarily by eating or antacids.
• Diarrhea – watery, sometimes fatty stools due to acid inactivation of pancreatic enzymes.
• Steatorrhea – fatty, foul‑smelling stools, indicating malabsorption.
• Nausea & vomiting – especially after meals.
• Weight loss – from chronic diarrhea and malabsorption.
• Gastroesophageal reflux disease (GERD) – heartburn, regurgitation.
• Gastro‑intestinal bleeding – melena (black tarry stools) or hematemesis (vomiting blood).
• Peptic ulcer complications – perforation (sudden severe abdominal pain) or obstruction (vomiting, bloating).
• Hypercalcemia – in MEN‑1 patients; may cause fatigue, bone pain, or kidney stones.

Causes and Risk Factors

Primary cause – Gastrinoma

A gastrinoma is a neuroendocrine tumor that secretes large amounts of gastrin, a hormone that stimulates gastric parietal cells to produce acid. The majority (≈60 %) arise in the “gastrinoma triangle” (duodenum, pancreas, and the connective tissue around the superior mesenteric artery). When these tumors grow, they cause unregulated acid output (up to 10–100 times normal levels).<sup>[2]</sup>

Risk factors

• MEN‑1 syndrome – hereditary mutation in the MEN1 gene; 20–30 % of ZES patients have this condition.
• Family history of gastrinoma – rare but increases risk.
• Age – incidence rises after the third decade.
• Smoking – may promote tumor growth and ulcer formation.
• Chronic use of NSAIDs or steroids – can worsen ulcer disease, though they are not causative for gastrinomas.

Diagnosis

Diagnosing ZES requires confirming hypergastrinemia, ruling out other causes of high gastrin, and locating the tumor.

Step‑by‑step approach

1. Clinical suspicion – refractory ulcers, ulcer disease beyond the duodenum, or recurrent ulcers despite proton‑pump inhibitor (PPI) therapy.
2. Fasting serum gastrin level – a level >1000 pg/mL (normal <100 pg/mL) in the presence of low gastric pH strongly suggests ZES.<sup>[3]</sup>
3. Secretin stimulation test – paradoxical rise in gastrin after IV secretin administration (>120 pg/mL rise) confirms gastrinoma when fasting gastrin is equivocal.
4. Imaging to locate tumor:
   • Multiphasic contrast CT or MRI of the abdomen.
   • Endoscopic ultrasound (EUS) – highly sensitive for small pancreatic lesions.
   • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – useful for detecting metastases.
5. Upper endoscopy (EGD) – visualizes ulcer location, checks for bleeding, and obtains biopsies to exclude malignancy.
6. Biopsy of the tumor (if accessible) – confirms neuroendocrine histology (chromogranin A, synaptophysin positive).

Treatment Options

Management targets two goals: control acid hypersecretion and remove or control the tumor.

Acid‑suppression therapy (first line)

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60 mg/day, esomeprazole 40 mg/day, or equivalent. Most patients achieve symptom control and ulcer healing within 2–4 weeks.<sup>[4]</sup>
• H2‑receptor antagonists – used only when PPIs are contraindicated; less effective for ZES.

Surgical management

Indications include localized tumors amenable to resection, symptomatic disease despite maximal medical therapy, or metastatic disease requiring debulking.

• Enucleation – removal of small, well‑circumscribed tumors.
• Pancreaticoduodenectomy (Whipple procedure) – for larger pancreatic lesions.
• Distal pancreatectomy – for tumors in the pancreatic body/tail.
• Liver metastasectomy – when solitary hepatic lesions are present.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – reduce gastrin secretion and may shrink tumor size.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive neuroendocrine tumors.
• Chemotherapy – reserved for high‑grade neuroendocrine carcinomas; regimens include streptozocin‑based combos.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for patients with somatostatin‑receptor positive disease.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and alcohol, which aggravate ulcer formation.
• Adopt a low‑fat, low‑acid diet; chew food slowly to reduce gastric stimulus.
• Maintain adequate hydration and replace electrolytes if chronic diarrhea occurs.
• Supplement fat‑soluble vitamins (A, D, E, K) and calcium if malabsorption is present.

Living with Zollinger’s Ulcers

Daily management tips

• Medication adherence – take PPIs at the same time each day, preferably 30 minutes before breakfast.
• Regular follow‑up – serum gastrin and endoscopic surveillance every 6–12 months, or sooner if symptoms change.
• Monitor for diarrhea – keep a stool diary; inform your physician of any sudden increase.
• Nutrition – small, frequent meals; consider medium‑chain triglyceride (MCT) oil if fat malabsorption is an issue.
• Bone health – chronic PPI use can affect calcium absorption; obtain a baseline DEXA scan and discuss supplementation.
• Stress management – techniques such as mindfulness or gentle yoga can reduce abdominal discomfort.

Support resources

Connect with patient advocacy groups like the North American Neuroendocrine Tumor Society (NANETS) for education, counseling, and clinical trial information.

Prevention

Because gastrinomas are usually sporadic, primary prevention is limited. However, risk can be lowered by:

• Avoiding chronic use of ulcer‑causing medications (NSAIDs, high‑dose steroids).
• Quitting smoking and limiting alcohol intake.
• Maintaining a healthy weight and balanced diet to reduce gastro‑intestinal irritation.
• For individuals with MEN‑1, undergoing genetic counseling and routine screening for neuroendocrine tumors.

Complications

If untreated or poorly controlled, Zollinger’s ulcers can lead to serious health problems:

• Gastro‑intestinal bleeding – may require transfusion or endoscopic therapy.
• Perforation – sudden, severe abdominal pain; surgical emergency.
• Obstruction – due to edema or scarring; may need dilation or surgery.
• Metastatic disease – liver, lymph nodes, or bone spread in 60–80 % of patients at diagnosis.
• Infectious complications – ulcer‑related bacterial overgrowth or Clostridioides difficile infection from frequent acid suppression.
• Nutritional deficiencies – iron, vitamin B12, folate, and fat‑soluble vitamin deficits from chronic diarrhea and malabsorption.
• Bone demineralization – long‑term PPIs and malabsorption increase fracture risk.

When to Seek Emergency Care

Key Take‑aways

• Zollinger’s ulcers are caused by gastrin‑producing neuroendocrine tumors that lead to massive acid output.
• High‑dose PPIs control symptoms in most patients; surgery offers the chance for cure when tumors are resectable.
• Regular monitoring, nutritional support, and awareness of alarm symptoms are essential for long‑term health.
• Seek immediate medical attention for any signs of bleeding, perforation, or severe pain.

For further reading, consult the following reputable sources:

• Mayo Clinic – Zollinger‑Ellison Syndrome
• Cleveland Clinic – Zollinger‑Ellison Syndrome Overview
• National Institutes of Health (NIH) – Neuroendocrine Tumors
• World Health Organization – Peptic Ulcer Disease Fact Sheet

```